Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co.
SEC Form 4 Filing
Lilly Endowment Inc., a major shareholder of Eli Lilly & Co., executed multiple sales of common stock on February 19, 2025, at weighted average prices ranging from $877.373 to $880.443.
Summary
- On February 19, 2025, Lilly Endowment Inc. sold shares of Eli Lilly & Co. common stock in multiple transactions.
- The sales were executed at weighted average prices ranging from $877.373 to $880.443 per share.
- A total of 4,836 shares were sold at an average price of $877.373.
- An additional 1,467 shares were sold at an average price of $878.508.
- Further sales included 2,389 shares at an average price of $879.5 and 1,293 shares at an average price of $880.443.
- Following these transactions, Lilly Endowment Inc. still beneficially owns 96,636,547 shares of Eli Lilly & Co. common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a share sale. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.
Industry Context
Form 4 filings are standard disclosures for significant shareholders, providing transparency into their transactions and holdings in publicly traded companies. This sale could be for portfolio rebalancing or other investment strategies of the endowment.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for insiders and large shareholders in publicly traded companies like Eli Lilly & Co.
- Comparable companies such as Pfizer (PFE) and Johnson & Johnson (JNJ) also have similar filings when their major shareholders or insiders trade their stock.
- The reported transactions are within the typical range of activity observed in insider trading disclosures.
Stakeholder Impact
- The sale of shares by a major shareholder like Lilly Endowment Inc. could have a minor impact on the stock price of Eli Lilly & Co., although the effect is likely to be minimal given the relatively small number of shares sold compared to the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 02/19/2025 | Date of the transactions (sale of shares). |
| 02/20/2025 | Date of signature for the Form 4 filing. |
Keywords
Eli Lilly & Co, Lilly Endowment Inc, Share Sale, Form 4, Beneficial Ownership, LLY
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.